Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating MF1, a new drug aimed at targeting the underlying pathological mechanisms of alpha-synucleinopathies, primarily Parkinsons disease PD. This Phase I first-in-human study seeks to assess the safety, tolerability, and pharmacokinetics of MF1, addressing a critical unmet medical need as current therapies only treat symptoms without modifying disease progression. The study involves healthy Japanese male adults and patients with idiopathic PD, reflecting different stages of clinical development. The trial has three parts Part A tests single ascending oral doses of MF1 and includes a food-effect assessment in healthy males aged 18 to under 45 years. Part B administers once-daily MF1 or placebo for 7 days in the same healthy population. Part C is an open-label study giving once-daily MF1 for 14 days to patients aged 40 to under 85 years with idiopathic PD Hoehn & Yahr stage 3 or below, with or without stable background antiparkinsonian treatments. The study also evaluates cerebrospinal fluid penetration and exploratory biomarkers related to neurodegeneration. Participants will undergo safety monitoring including adverse event assessments and pharmacokinetic sampling of plasma, urine, and cerebrospinal fluid. Biomarkers such as alpha-synuclein and others will be measured to explore pharmacodynamic effects. The study includes randomized, placebo-controlled parts in healthy volunteers and an open-label part in PD patients, with follow-up for up to 12 days after dosing. The total participation duration varies by study part, with careful review before progressing between stages.
Actively Recruiting
Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.
Actively Recruiting
Researchers are studying chronic primary immune thrombocytopenia ITP, a condition where the immune system mistakenly destroys platelets, leading to easier bruising and bleeding due to low platelet counts. The trial aims to evaluate whether mezagitamab, given as a subcutaneous injection, can maintain stable platelet levels in adults with ITP compared to a placebo. This Phase 3 study is randomized, double-blind, and placebo-controlled to thoroughly assess mezagitamabs effects. Participants will receive either mezagitamab or a matching placebo injection once weekly. The dosing schedule includes 8 weeks of weekly injections, followed by an 8-week break, and then another 8 weeks of weekly injections, totaling up to 6 months of treatment. Those who complete this study or do not respond by week 16 may have the option to join a continuation study to receive open-label mezagitamab if eligible. During the study, participants will visit the clinic multiple times for assessments. Researchers will monitor platelet counts regularly and evaluate responses using measures such as the percentage of participants with durable platelet response up to week 24. Additional assessments include symptom questionnaires, fatigue scores, bleeding events, and monitoring of mezagitamab levels and antibodies. The study also observes safety and treatment effects through week 24 and beyond as needed.
Actively Recruiting
Polycythemia vera PV is a rare blood cancer where the body produces too many red blood cells, causing thicker blood and increasing the risk of blood clots. This study evaluates whether the drug rusfertide can help Japanese adults with PV control their hematocrit levels and reduce the need for regular blood removal phlebotomy. It is an open-label Phase 2 trial, meaning both participants and researchers know the treatment being given. Participants will receive weekly subcutaneous injections of rusfertide for an initial 52-week treatment period, followed by a long-term extension phase lasting up to 182 weeks. The study includes a screening period before treatment and a 4-week safety follow-up after treatment ends. The goal is to assess rusfertides ability to maintain hematocrit control and decrease phlebotomy requirements over this extended time. During the trial, participants will be regularly monitored through blood tests to measure hematocrit and other blood components. Researchers will track the number of phlebotomies needed, the participants response to treatment from weeks 20 to 32, and safety during and after treatment. Overall, participants may be involved for up to about 244 weeks, with ongoing assessments to evaluate the drugs effects and monitor health status.
Actively Recruiting
Narcolepsy Type 2 NT2 is a lifelong condition causing excessive daytime sleepiness and difficulty staying awake, which can disrupt daily activities and quality of life. Researchers are studying TAK-360, a drug that acts like the brain chemical orexin, to evaluate its safety, tolerability, and potential to help adults with NT2 stay awake. This Phase 2 trial also aims to determine the right dosage of TAK-360. Participants will be randomly assigned to receive either TAK-360 tablets or matching placebo tablets orally for 4 weeks. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. Throughout the study, participants will be monitored for treatment-emergent adverse events up to 15 weeks. Researchers will measure changes from baseline to week 4 in sleepiness using the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test. This helps evaluate how well TAK-360 helps participants stay awake and alert during the day.
Actively Recruiting
Researchers are studying adults with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This trial aims to compare the levels of drug exposure following treatment with tislelizumab given as a subcutaneous injection versus an intravenous infusion as first-line therapy. The study includes approximately 351 participants and is sponsored by BeOne Medicines. Participants are randomly assigned to one of two groups one group receives tislelizumab 300 mg as a subcutaneous injection on Day 1 of each 21-day cycle, followed by chemotherapy chosen individually the other group receives tislelizumab 200 mg as an intravenous infusion on Day 1 of each 21-day cycle, also followed by individualized chemotherapy. Chemotherapy drugs may include cisplatin, leucovorin, 5-fluorouracil, oxaliplatin, or capecitabine. The study is divided into a screening period, a treatment period, and a follow-up period. Throughout the study, participants will be monitored for drug levels, tumor response, survival, and adverse events for up to two years. Assessments include measuring the steady state trough concentration and area under the concentration-time curve of tislelizumab, as well as evaluating tumor response rates and disease control. Safety and antibody responses will also be tracked. Participants will undergo regular visits to collect medical data and ensure adherence to the treatment plan during the study period.
Actively Recruiting
Crohns disease is a chronic inflammatory condition affecting the digestive tract and is currently incurable. This research aims to evaluate how safe and effective the drug upadacitinib is for treating moderately to severely active Crohns disease in real-world settings. The study will monitor any adverse events and track changes in disease activity among participants. All participants will receive upadacitinib as prescribed by their own doctors according to approved local guidelines. The study plans to enroll about 240 participants in Japan who have recently started upadacitinib treatment. Treatment will follow routine clinical practice without altering the prescribed approach. Participants will be followed for up to 64 weeks with visits that may occur in person or virtually, aligned with standard care. Researchers will assess outcomes such as the percentage of participants experiencing serious infections related to the drug. There is expected to be no extra burden beyond usual medical care throughout the study period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, and how the body processes and responds to HJB647 in Japanese adults with elevated blood pressure and hypertension. This randomized, placebo-controlled, double-blind Phase 1b study includes healthy participants with elevated blood pressure and patients with mild-to-moderate hypertension to support future development of HJB647. The study has two parts Part 1 tests a single oral dose of HJB647 in healthy participants using sentinel dosing within each cohort, while Part 2 involves multiple oral doses with adaptive dose escalation and up-titration in hypertensive patients. Both parts include placebo groups for comparison. Participants will be monitored through scheduled visits with assessments including blood pressure and heart rate measurements, pharmacokinetic and pharmacodynamic evaluations, and safety reviews. Part 1 outcomes focus on drug concentration and timing measures after a single dose, while Part 2 monitors adverse events and changes in blood pressure and heart rate up to 51 days. The study runs from July to December 2026.